No End to Uncertainty about Inhaled Glucocorticoids in Preterm Infants  

Oleh:

Schmidt, Barbara

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 373 no. 16 (Oct. 2015), page 1566-1567.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Bronchopulmonary dysplasia, a chronic neonatal lung disease, affects at least 10,000 preterm infants in the United States each year. It is caused by acute lung injury due to surfactant insufficiency, artificial ventilation, the use of supplemental oxygen, and inflammation, followed by abnormal repair and impaired lung growth.1 Bronchopulmonary dysplasia is the single most common complication that occurs in extremely preterm infants (those who are born at <28 weeks of gestation) or extremely-low-birth-weight infants (those who weigh <1000 g at birth) during their initial hospitalization.1 This respiratory complication, which is typically diagnosed at a postmenstrual age of 36 weeks, is defined as treatment with positive airway pressure or supplemental oxygen in the setting of neonatal care.2 Bronchopulmonary dysplasia is associated with increased risks of death among infants and children, growth failure, neurodevelopmental delay, and cardiopulmonary impairment lasting into adolescence and young adulthood.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali